FibroGen to Participate in Upcoming Investor Conferences
07 Mai 2024 - 1:00PM
FibroGen, Inc. (NASDAQ: FGEN) today announced that the
company’s management will participate in the following investor
conferences:
Bank of America Health Care
Conference Format: 1x1 investor meetings Date: Tuesday,
May 14, 2024 Location: Las Vegas, NV
H.C. Wainwright
2nd Annual Bioconnect Investor
Conference Format: Fireside Chat and 1x1 investor meetings
Date: Monday, May 20, 2024 Fireside Chat Time: 5:00 – 5:30 PM ET
Location: New York, NY
The live audio webcast of the H.C. Wainwright
Fireside Chat will be available to investors and other interested
parties on the “Events & Presentations” section of the FibroGen
Investor webpage at www.fibrogen.com. A replay will be
available for 30 days.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company focused on accelerating the development
of novel therapies at the frontiers of cancer biology. Pamrevlumab,
a fully human anti-CTGF monoclonal antibody, is in clinical
development for the treatment of metastatic pancreatic cancer and
locally advanced unresectable pancreatic cancer (LAPC). Roxadustat
(爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan,
and numerous other countries for the treatment of anemia in chronic
kidney disease (CKD) patients on dialysis and not on dialysis.
Roxadustat is in clinical development for chemotherapy-induced
anemia (CIA) and a Supplemental New Drug Application (sNDA) has
been accepted for review by the China Health Authority. FG-3246
(also known as FOR46), a first-in-class antibody-drug conjugate
(ADC) targeting CD46 is in development for the treatment of
metastatic castration-resistant prostate cancer. This program also
includes the development of an associated CD46-targeted PET
biomarker. In addition, FibroGen has expanded its research and
development portfolio to include two immuno-oncology product
candidates for the treatment of solid tumors. For more information,
please visit www.fibrogen.com.
FibroGen, Inc.
Investors:David DeLucia, CFAVice
President of Corporate FP&A / Investor
Relationsir@fibrogen.com
Media:Meichiel KeenanDirector,
Investor Relations and Corporate
Communicationsmedia@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
